Blend Therapeutics, a biotechnology firm founded by Dr. Omid Farokhzad, Director of Laboratory of Nanomedicine and Biomaterials at Harvard Medical School, and Dr. Stephen Lippard and Dr. Robert Langer, Professors from the Massachusetts Institute of Technology, has declared its founding mission.
According to the strategic mission, Blend Therapeutics will develop novel integrative combination medicines with innovative pharmacological profiles that efficiently and safely target the pathways of distinct diseases. The company’s Maestro platform for developing new class of pharmacologically controlled combination medicines is its cornerstone. It has received funds from top-tier venture investors such as NanoDimension, New Enterprise Associates and Flagship Ventures.
Blend Therapeutics uses its proprietary Maestro platform in integrative pharmacology and mechanism-directed molecular design nanoparticle engineering technologies to produce clinically efficient combination medicines. This novel platform allows the company to enhance the pharmacological response of combination medicines, especially to drugs reach their target areas at the optimal time and ensure efficient drug ratios and concentrations.
Blend Therapeutics has also declared the launch of its Scientific Advisory Board (SAB), with eight members, who are experts in the fields of medicine, immunology, cancer biology and chemistry from a broad array of top medical centers and academic institutions. SAB will help the company in the development of its Maestro platform to produce combination medicines for treating complex diseases.
Source: http://www.blendtx.com